前立腺肥大症に対するTSAA-291の臨床効果 -Robaveronとの比較対照試験-

概要

論文の詳細を見る
Comparative study was carried out in 185 patients with benign prostatic hyperplasia in order to estimate the clinical effectiveness of TSAA-291 and Robaveron. 1) 68 patients on TSAA-291 and 58 patients on Rovaberon were included in comparative analyses. 2) Clinical effectiveness was evaluated by means of scoring improvement of subjective symptoms associated with benign prostatic hyperplasia and physical findings such as rectal examination, residual urine, uroflowmetry, urethrocystography and histological findings. 3) Clinical effectiveness in TSAA-291-treated patients was significantly greater than that in Robaveron-treated patients (p<0.01). The rate of effectiveness was 81.8% for TSAA-291. 4) Improvement rates of both subjective symptoms and objective findings, in TSAA-291-treated patients were significantly greater than those in Robaveron-treated patients (p<0.05). 5) The tendency of decreasing size of the prostate in TSAA-291 treated patients was observed by rectal examination(p <0.05), but the length of the prostatic urethra was not shorter on urethrocystograph. 6) Prostatic needle biopsy was performed in TSAA-291-treated 8 patients. The atrophy of prostatic acini was observed in 5 cases. 7) Side effects were noted in 5 of 91 cases on TSAA-291 of them, 4 cases complained of pain in the area of injection, and in I case slight elevation of BUN was observed. The findings indicate that TSAA-291 is a useful drug in conservative treatment for benign prostatic hyperplasia.
泌尿器科紀要刊行会の論文

前立腺肥大症に対するTSAA-291の臨床効果 -Robaveronとの比較対照試験-

スポンサーリンク

概要

著者

関連論文

スポンサーリンク